Heparan Sulfate Clinical Trials

Size	Price	Qty
5mg	USD 159
25mg	USD 477

Clinical Trials

Multiple clinical trials evaluate conditions associated with heparan sulfate pathways, recombinant enzyme derivatives, and specialized therapeutic formulations across Phase I through Phase III studies. Sponsored by academic medical centers and pharmaceutical organizations, these investigations cover indications ranging from Sanfilippo syndrome and vascular conditions to oncological diseases and dermatological scarring. Recruitment statuses across these protocols vary, encompassing completed, active, not yet recruiting, withdrawn, and terminated studies.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06567769	RECRUITING	Sanfilippo Syndrome Type A	GC Biopharma Corp	2024-11-21	PHASE1
NCT07684833	NOT_YET_RECRUITING	Chronic Venous Disease; Vein Disease; Venous Insufficiency of Leg	Barbara Maglione	2026-11	PHASE3
NCT06052423	Withdrawn	Extensive Stage Small Cell Lung Cancer (ES-SCLC)	Hansoh BioMedical R&D Company	2024-11-30	Phase 2
NCT05928078	Not yet recruiting	Cognitive Decline	University of Castilla-La Mancha	2024-09-01	Not Applicable
NCT06208735	Not yet recruiting	B-Cell Leukemia\|Non-Hodgkin''s Lymphoma\|B-cell Acute Lymphoblastic Leukemia\|Diffuse Large B Cell Lymphoma\|High-grade B-cell Lymphoma\|Primary Mediastinal Large B-cell Lymphoma (PMBCL)\|Mantle Cell Lymphoma\|B-cell Lymphoma	British Columbia Cancer Agency	2024-07-01	Phase 1
NCT05470322	Not yet recruiting	Hidradenitis Suppurativa\|Scarring	Montefiore Medical Center	2024-06	Not Applicable
NCT06118281	Not yet recruiting	Cardiovascular Risk\|Acute Myocardial Infarction (AMI)	Novo Nordisk A/S\|Duke Clinical Research Institute	2024-06-25	Phase 3
NCT02350816	TERMINATED	Sanfilippo Syndrome; Mucopolysaccharidosis (MPS)	Shire	2015-04-08	PHASE2
NCT02060526	COMPLETED	Sanfilippo Syndrome	Shire	2014-02-26	PHASE2
NCT01155778	COMPLETED	Mucopolysaccharidosis (MPS)	Shire	2010-06-01	PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2025-08-28)

Check the Heparan Sulfate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Heparan sulfate functions as a cell-surface glycosaminoglycan that binds extracellular signaling ligands and cell receptors—such as enhancing Wnt binding in intestinal epithelial cells—thereby activating canonical downstream signaling pathways to stimulate cellular proliferation, matrix organization, and tissue regeneration. This essential involvement in cell-surface receptor binding, signal modulation, and structural turnover underscores its therapeutic relevance in managing lysosomal storage disorders like Sanfilippo syndrome and restoring vascular tissue integrity in chronic venous disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).